Andrade Diocésio Alves Pinto de, Zucca-Matthes Gustavo, Vieira René Aloísio da Costa, Andrade Cristiane Thomaz de Aquino Exel de, Costa Allini Mafra da, Monteiro Aurélio Julião de Castro, Dal Lago Lissandra, Nunes João Soares
Einstein (Sao Paulo). 2013 Dec;11(4):446-50. doi: 10.1590/s1679-45082013000400007.
To evaluate the complete pathologic response attained by patients diagnosed with locally advanced breast cancer submitted to neoadjuvant chemotherapy based on the doxorubicin/cyclophosphamide regimen followed by paclitaxel.
A retrospective cohort of patients with locally advanced breast cancer, admitted to the Hospital de Câncer de Barretos between 2006 and 2008 submitted to the doxorubicin/cyclophosphamide protocol followed by paclitaxel (4 cycles of doxorubicin 60mg/m² and cyclophosphamide 600mg/m² every 21 days; 4 cycles of paclitaxel 175mg/m² every 21 days). The following variables were assessed: age, menopause, performance status, initial clinical staging, anthropometric data, chemotherapy (dose - duration), toxicity profile, post-treatment staging, surgery, pathologic complete response rate, disease-free survival, and pathological characteristics (type and histological degree, hormonal profile and lymph node involvement). Statistical analysis was performed using a 5% level of significance.
Of the 434 patients evaluated, 136 were excluded due to error in staging or because they had received another type of chemotherapy. Median age was 50 years, all with performance status 0-1. Median initial clinical size of tumor was 65mm and the median final clinical size of the tumor was 22mm. Fifty-one (17.1%) patients experienced a pathologic complete response. Those with a negative hormonal profile or who were triple-negative (negative Her-2 and hormonal profile) experienced a favorable impact on the pathologic complete response.
Neoadjuvant chemotherapy with doxorubicin/cyclophosphamide followed by paclitaxel provided a pathologic complete response in the population studied in accordance with that observed in the literature. Triple-negative patients had a greater chance of attaining this response.
评估接受基于阿霉素/环磷酰胺方案序贯紫杉醇的新辅助化疗的局部晚期乳腺癌患者获得的完全病理缓解情况。
对2006年至2008年间入住巴雷托斯癌症医院的局部晚期乳腺癌患者进行回顾性队列研究，这些患者接受阿霉素/环磷酰胺方案序贯紫杉醇治疗（阿霉素60mg/m²和环磷酰胺600mg/m²每21天进行4个周期；紫杉醇175mg/m²每21天进行4个周期）。评估以下变量：年龄、绝经状态、体能状态、初始临床分期、人体测量数据、化疗（剂量 - 疗程）、毒性特征、治疗后分期、手术、病理完全缓解率、无病生存期以及病理特征（类型和组织学分级、激素谱和淋巴结受累情况）。采用5%的显著性水平进行统计分析。
在评估的434例患者中，136例因分期错误或接受了其他类型化疗而被排除。中位年龄为50岁，所有患者体能状态为0 - 1。肿瘤初始临床大小中位数为65mm，最终临床大小中位数为22mm。51例（17.1%）患者获得病理完全缓解。激素谱阴性或三阴性（Her-2和激素谱均为阴性）的患者对病理完全缓解有积极影响。
阿霉素/环磷酰胺序贯紫杉醇的新辅助化疗在所研究人群中提供了与文献报道一致的病理完全缓解。三阴性患者获得这种缓解的机会更大。
